Robert Charles Breedlove

CIK: 0002066645

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (25.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)6 (50.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

PHAT

Phathom Pharmaceuticals, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

PHAT
Phathom Pharmaceuticals, Inc.
Sep 3, 2026
Tax Payment(F)
Direct
460 shares at avg. $9.05$4K
PHAT
Phathom Pharmaceuticals, Inc.
Jul 14, 2026
Tax Payment(F)
Direct
1.6K shares at avg. $11.04$17K
PHAT
Phathom Pharmaceuticals, Inc.
Feb 27, 2026
Award(A)
Direct
13K shares-
PHAT
Phathom Pharmaceuticals, Inc.
Feb 27, 2026
Tax Payment(F)
Direct
414 shares at avg. $12.56$5K
PHAT
Phathom Pharmaceuticals, Inc.
Feb 27, 2026
Award(A)
Direct
2.8K shares-
PHAT
Phathom Pharmaceuticals, Inc.
Feb 27, 2026
Tax Payment(F)
Direct
964 shares at avg. $12.56$12K
PHAT
Phathom Pharmaceuticals, Inc.
Jan 21, 2026
Tax Payment(F)
Direct
776 shares at avg. $13.61$11K
PHAT
Phathom Pharmaceuticals, Inc.
Dec 18, 2025
Tax Payment(F)
Direct
230 shares at avg. $16.28$4K
PHAT
Phathom Pharmaceuticals, Inc.
Nov 3, 2025
Sale(S)
Direct
524 shares at avg. $13.51$7K
PHAT
Phathom Pharmaceuticals, Inc.
Sep 5, 2025
Sale(S)
Direct
461 shares at avg. $12.09$6K
PHAT
Phathom Pharmaceuticals, Inc.
Jul 16, 2025
Sale(S)
Direct
1.7K shares at avg. $8.36$14K
PHAT
Phathom Pharmaceuticals, Inc.
May 19, 2025
Award(A)
Stock Option (Right to Buy)
Direct
33K shares-

		Type	Shares	Price		Ownership
Sep 3, 2026	PHAT Phathom Pharmaceuticals, Inc.	Tax Payment(F)	460	$9.05	$4,163	Direct
Jul 14, 2026	PHAT Phathom Pharmaceuticals, Inc.	Tax Payment(F)	1,555	$11.04	$17,159	Direct
Feb 27, 2026	PHAT Phathom Pharmaceuticals, Inc.	Award(A)	13,000	-	$0	Direct
Feb 27, 2026	PHAT Phathom Pharmaceuticals, Inc.	Tax Payment(F)	414	$12.56	$5,200	Direct
Feb 27, 2026	PHAT Phathom Pharmaceuticals, Inc.	Award(A)	2,790	-	$0	Direct
Feb 27, 2026	PHAT Phathom Pharmaceuticals, Inc.	Tax Payment(F)	964	$12.56	$12,108	Direct
Jan 21, 2026	PHAT Phathom Pharmaceuticals, Inc.	Tax Payment(F)	776	$13.61	$10,561	Direct
Dec 18, 2025	PHAT Phathom Pharmaceuticals, Inc.	Tax Payment(F)	230	$16.28	$3,744	Direct
Nov 3, 2025	PHAT Phathom Pharmaceuticals, Inc.	Sale(S)	524	$13.51	$7,079	Direct
Sep 5, 2025	PHAT Phathom Pharmaceuticals, Inc.	Sale(S)	461	$12.09	$5,573	Direct
Jul 16, 2025	PHAT Phathom Pharmaceuticals, Inc.	Sale(S)	1,692	$8.36	$14,152	Direct
May 19, 2025	PHAT Phathom Pharmaceuticals, Inc.	Award(A) Stock Option (Right to Buy)	33,000	-	-	Direct

1-12 of 12 transactions

About Breedlove Robert Charles

Breedlove Robert Charles (SEC CIK 0002066645) files insider reports with the SEC as Principal Accounting Officer of Phathom Pharmaceuticals, Inc. (PHAT).

Signal8 holds 10 ownership filings by Breedlove Robert Charles (1 Form 3, 9 Form 4), filed between May 6, 2025 and Sep 8, 2026. Those filings report 12 transactions, from May 19, 2025 to Sep 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Breedlove Robert Charles's filings is in FLORHAM PARK, NJ.

Recent filings by Breedlove Robert Charles

Sep 3, 2026: Tax withholding of PHAT shares (Form 4, code F).
Jul 14, 2026: Tax withholding of PHAT shares (Form 4, code F).
Feb 27, 2026: Grant or award of PHAT shares (Form 4, code A).
Feb 27, 2026: Tax withholding of PHAT shares (Form 4, code F).
Feb 27, 2026: Grant or award of PHAT shares (Form 4, code A).

Other insiders filing for Phathom Pharmaceuticals, Inc. (PHAT)

Narula Sanjeev, Chief Financial & Bus. Officer
Parikh Asit, Director
Topper James N, Director
Stenhouse Mark, Director
FIELDS HEIDI, Director
COLA MICHAEL F, Director

How to read Form 4 transaction codes